Recombinant multi-species LYPLA3/PLA2G15 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine LYPLA3/PLA2G15 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Lysophospholipases are enzymes that act on biological membranes to regulate the multifunctional lysophospholipids. The protein encoded by this gene hydrolyzes lysophosphatidylcholine to glycerophosphorylcholine and a free fatty acid. This enzyme is present in the plasma and thought to be associated with high-density lipoprotein. A later paper contradicts the function of this gene. It demonstrates that this gene encodes a lysosomal enzyme instead of a lysophospholipase and has both calcium-independent phospholipase A2 and transacylase activities. [provided by RefSeq, Jul 2008]
The Alternative Names of target: 1-O-acylceramide synthase (ACS),1-O-acylceramidesynthase,ACS,GXVPLA2,LCAT-like lysophospholipase (LLPL),LLPL,LPLA2,LYPLA3,Lpla2,Lypla3,Lysophospholipase 3,Lysosomal phospholipase A and acyltransferase,Lysosomal phospholipase A2 (LPLA2),PLA2G15,Phospholipase A2 group XV (PLA2G15),Pla2g15

Target products collectionGo to LYPLA3/PLA2G15 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0410-Ag-1/ GM-Tg-hg-SE0410-Ag-2 Human LYPLA3/PLA2G15 protein Human
GM-Tg-rg-SE0410-Ag-1/ GM-Tg-rg-SE0410-Ag-2 Rat LYPLA3/PLA2G15 protein Rat
GM-Tg-mg-SE0410-Ag-1/ GM-Tg-mg-SE0410-Ag-2 Mouse LYPLA3/PLA2G15 protein Mouse
GM-Tg-cynog-SE0410-Ag-1/ GM-Tg-cynog-SE0410-Ag-2 Cynomolgus/Rhesus macaque LYPLA3/PLA2G15 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0410-Ag-1/ GM-Tg-felg-SE0410-Ag-2 Feline LYPLA3/PLA2G15 protein Feline
GM-Tg-cang-SE0410-Ag-1/ GM-Tg-cang-SE0410-Ag-2 Canine LYPLA3/PLA2G15 protein Canine
GM-Tg-bovg-SE0410-Ag-1/ GM-Tg-bovg-SE0410-Ag-2 Bovine LYPLA3/PLA2G15 protein Bovine
GM-Tg-equg-SE0410-Ag-1/ GM-Tg-equg-SE0410-Ag-2 Equine LYPLA3/PLA2G15 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0410-Ag-1/ GM-Tg-hg-SE0410-Ag-2; GM-Tg-rg-SE0410-Ag-1/ GM-Tg-rg-SE0410-Ag-2;
GM-Tg-mg-SE0410-Ag-1/ GM-Tg-mg-SE0410-Ag-2; GM-Tg-cynog-SE0410-Ag-1/ GM-Tg-cynog-SE0410-Ag-2;
GM-Tg-felg-SE0410-Ag-1/ GM-Tg-felg-SE0410-Ag-2; GM-Tg-cang-SE0410-Ag-1/ GM-Tg-cang-SE0410-Ag-2;
GM-Tg-bovg-SE0410-Ag-1/ GM-Tg-bovg-SE0410-Ag-2; GM-Tg-equg-SE0410-Ag-1/ GM-Tg-equg-SE0410-Ag-2
Products Name LYPLA3/PLA2G15 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name LYPLA3/PLA2G15
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine LYPLA3/PLA2G15 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.